12:00 AM
 | 
May 18, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Low dose aspirin/esomeprazole magnesium combination product regulatory update

AstraZeneca submitted an NDA to FDA for its low dose aspirin/esomeprazole magnesium combination product to reduce the risk of low dose...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >